A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.

被引：6
|
作者：
van Bussel, Mark
Mau-Soerensen, Morten
Damstrup, Lars
Nielsen, Dorte
Verheul, Henk M. W.
Aftimos, Philippe Georges
De Jonge, Maja J.
Berghoff, Karin
Schellens, Jan H. M.
机构：
[1] Netherlands Canc Inst NKI, Amsterdam, Netherlands
[2] Rigshosp, Dept Oncol, Copenhagen, Denmark
[3] Merck KGaA, Darmstadt, Germany
[4] Herlev Hosp, Dept Oncol, Herlev, Denmark
[5] Canc Ctr, Dept Med Oncol, Amsterdam, Netherlands
[6] Inst Jules Bordet, Brussels, Belgium
[7] Erasmus MC, Canc Inst, Rotterdam, Netherlands
[8] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2556
引用
收藏
页数：5
相关论文
共 50 条
  • [21] DNA-BINDING BY THE THE HUMAN DNA-DEPENDENT PROTEIN-KINASE, DNA-PK
    POLTORATSKY, V
    MALIK, N
    SAMSON, G
    LIEBER, M
    CARTER, T
    FASEB JOURNAL, 1995, 9 (06): : A1394 - A1394
  • [22] Regulation of the DNA-dependent protein kinase (DNA-PK) activity in eukaryotic cells
    Muller, C
    Calsou, P
    Frit, P
    Salles, B
    BIOCHIMIE, 1999, 81 (1-2) : 117 - 125
  • [23] The DNA-dependent protein kinase, DNA-PK: 10 years and no ends in sight
    LeesMiller, SP
    BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1996, 74 (04): : 503 - 512
  • [24] Design and synthesis of novel DNA-dependent protein kinase (DNA-PK) inhibitors
    Barbeau, OR
    Golding, BT
    Griffin, RJ
    Hardcastle, IR
    Smith, GCM
    Richardson, C
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2718 - U2718
  • [25] Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
    Wise, Hannah C.
    Iyer, Gopakumar V.
    Moore, Kathleen
    Temkin, Sarah M.
    Gordon, Sarah
    Aghajanian, Carol
    Grisham, Rachel N.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [26] Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
    Hannah C. Wise
    Gopakumar V. Iyer
    Kathleen Moore
    Sarah M. Temkin
    Sarah Gordon
    Carol Aghajanian
    Rachel N. Grisham
    Scientific Reports, 9
  • [27] A novel selective DNA-PK inhibitor, M3814, as a potential combination partner of Etoposide and Cisplatin in the therapy of lung cancer
    Sirrenberg, Christian
    Zimmermann, Astrid
    Grombacher, Thomas
    Vassilev, Lyubomir T.
    Damstrup, Lars
    Zenke, Frank T.
    Blaukat, Andree
    CANCER RESEARCH, 2017, 77
  • [28] Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine
    Block, WD
    Merkle, D
    Meek, K
    Lees-Miller, SP
    NUCLEIC ACIDS RESEARCH, 2004, 32 (06) : 1967 - 1972
  • [29] M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
    Wu, Zhuo-Xun
    Peng, Zheng
    Yang, Yuqi
    Wang, Jing-Quan
    Teng, Qiu-Xu
    Lei, Zi-Ning
    Fu, Yi-Ge
    Patel, Ketankumar
    Liu, Lili
    Lin, Lizhu
    Zou, Chang
    Chen, Zhe-Sheng
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [30] Highly potent and selective DNA-PK inhibitor M3814 with sustainable anti-tumor activity in combination with radiotherapy
    Fuchss, Thomas
    Mederski, Werner W.
    Emde, Ulrich
    Buchstallter, Hans-Peter
    Zenke, Frank
    Zimmermann, Astrid
    Sirrenberg, Christian
    Vassilev, Lubo
    Damstrup, Lars
    Urbahns, Klaus
    Blaukat, Andree
    CANCER RESEARCH, 2017, 77
12345